Overview

• Researchers refined the Agg-CLNP formulation for stability and targeted dendritic cell uptake, confirming significant suppression of dendritic cell activation in human blood samples.
• Preventative dosing of Agg-CLNP in mouse models delayed the onset of joint inflammation and swelling but showed minimal effect after disease establishment.
• Combining Agg-CLNP with abatacept postponed disease onset and reduced joint inflammation, swelling and bone damage compared with abatacept alone in mice.
• Agg-CLNP administered at peak dexamethasone efficacy mitigated withdrawal flares and sustained protective effects without causing systemic immunosuppression.
• Ongoing efforts include toxicity assessments, further formulation refinements and personalized nanoparticle design to prepare Agg-CLNP for clinical trials.